Clinical trial
A Prospective Phase 2 Study to Assess the Minimal Residual Disease After Ixazomib Plus Lenalidomide Plus Dexamethasone (IRd) Treatment for Newly Diagnosed Transplant Eligible Myeloma Patients
NCT03376672 is registered in ClinicalTrials.gov with Raija Silvennoinen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Phase 2 Study to Assess the Minimal Residual Disease After Ixazomib Plus Lenalidomide Plus Dexamethasone (IRd) Treatment for Newly Diagnosed Transplant Eligible Myeloma Patients
- Lead sponsor
- Raija Silvennoinen
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- May 31, 2018
- Completion date
- December 31, 2027
- Enrollment
- 120 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.